PharmaCyte Biotech Inc (PMCB)

[1234jklm]

Stem cells and encapsulation

Apart from all the other unique qualities of our encapsulation technology there's one more that's incredibly valuable for stem cell therapies. With ciab we can place stem cells in a particular site and anchor them there where they'll have the greatest effect on other cells. This is because ciab is large enough to get stuck there while also being small enough to inject.

I believe this is why Austrianova is about to be partnered because this is exactly the delivery method new stem cell therapies need. If you own the license to that you own the key to successful stem cell therapy. And that's the next frontier of medicine right now. And commercially regenerative stem cell treatment will be where the money is. And we own 14% of this. Good work mr Waggoner. Much much better than owning bio bluebird which we swapped for this.

Kw has been truly visionary in setting us up like this although I am sure that's tough for some others to hear.